Second Sight Medical Products Inc. (NASDAQ:EYES) shares dropped 2.4% during trading on Thursday . The company traded as low as $4.08 and last traded at $4.08, with a volume of 166,501 shares changing hands. The stock had previously closed at $4.18.

Separately, Zacks Investment Research downgraded Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Monday, April 4th.

The firm’s market cap is $145.95 million. The company’s 50-day moving average price is $3.82 and its 200-day moving average price is $4.56.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The business’s quarterly revenue was down 38.2% on a year-over-year basis. Analysts forecast that Second Sight Medical Products Inc. will post ($0.65) earnings per share for the current year.

In other news, Chairman Robert J. Greenberg sold 8,223 shares of the business’s stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the transaction, the chairman now directly owns 181,134 shares in the company, valued at $954,576.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Robert J. Greenberg sold 8,571 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total value of $35,141.10. Following the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at $708,935.10. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Zeke Capital Advisors LLC acquired a new stake in Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products comprises approximately 2.5% of Zeke Capital Advisors LLC’s holdings, making the stock its 10th largest position. Zeke Capital Advisors LLC owned about 1.38% of Second Sight Medical Products as of its most recent filing with the SEC.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.